Quick Answer
GT Biopharma, Inc. reported Total Assets of $8.11 million for fiscal year 2025.
GT Biopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $8.11M | +87.6% |
| 2025 | $4.32M | -39.3% |
| 2025 | $7.12M | +68.3% |
| 2024 | $4.23M | -70.0% |
| 2023 | $14.11M | -15.7% |
| 2022 | $16.74M | -48.0% |
| 2021 | $32.17M | +468.3% |
| 2020 | $5.66M | +1329.5% |
| 2019 | $396.0K | -98.4% |
| 2018 | $25.40M | -90.0% |
| 2017 | $254.37M | +1017372.0% |
| 2016 | $25.0K | -53.7% |
| 2015 | $54.0K | -93.9% |
| 2014 | $888.0K | +504.1% |
| 2013 | $147.0K | -35.0% |
| 2012 | $226.0K | +75.2% |
| 2011 | $129.0K | -30.3% |
| 2010 | $185.0K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $6.76M | -58.1% | -27.1% |
| June 30, 2024 | $9.27M | -48.9% | -6.5% |
| March 31, 2024 | $9.91M | -50.7% | -29.7% |
| December 31, 2023 | $14.11M | -15.7% | -12.6% |
| September 30, 2023 | $16.15M | -23.4% | -11.0% |
| June 30, 2023 | $18.14M | -24.9% | -9.7% |
| March 31, 2023 | $20.09M | -26.8% | +20.0% |
| December 31, 2022 | $16.74M | -48.0% | -20.6% |
- GT Biopharma, Inc. showed an increase of +87.6% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, GT Biopharma, Inc.’s total assets has grown by 4281.6% (from $185.0 thousand to $8.11 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: